Vericel Corporation ( (VCEL) ) has released its Q1 earnings. Here is a breakdown of the information Vericel Corporation presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vericel Corporation is a prominent player in the sports medicine and severe burn care markets, offering advanced cell therapies and specialty biologics designed to repair injuries and restore lives. The company has reported its financial results for the first quarter of 2025, highlighting record revenues and an optimistic outlook for the year.
In the first quarter of 2025, Vericel achieved a total net revenue of $52.6 million, with MACI revenue reaching a record $46.3 million. The company also reported a significant increase in burn care revenue, notably with NexoBrid seeing a 207% increase compared to the previous year. Despite a net loss of $11.2 million, the company maintained a strong gross margin of 69% and reported a positive operating cash flow of $6.6 million.
Vericel has trained approximately 400 MACI Arthro surgeons, contributing to a year-to-date biopsy growth of over 30% for these trained professionals. The company anticipates continued revenue growth in the low- to mid-20% range for the second quarter and has reaffirmed its full-year revenue guidance while raising its profitability guidance.
Looking ahead, Vericel is poised for continued growth, supported by strong performance indicators and strategic initiatives. The company is on track to initiate a MACI Ankle clinical study in the second half of 2025, and management remains confident in achieving high revenue and profit growth throughout the year and beyond.